Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kenvue Inc.KVUE · Entity 3098 | Chief Scientific Officer | October 02, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kenvue Inc.
Report date October 02, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,709.15 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Grant · Acquired 24,732 · Balance 86,180.15 F1: Represents the distribution of shares of common stock upon satisfaction of the performance criteria applicable to Performance Share Units (PSUs) granted on October 2, 2023. The PSUs vested at 100% of the target award and include dividend equivalents accrued during the three-year performance period. Row 2 · 2026-10-02 · Tax withholding · Disposed 8,471 · Balance 77,709.15 F2: Shares withheld for payment of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the distribution of shares of common stock upon satisfaction of the performance criteria applicable to Performance Share Units (PSUs) granted on October 2, 2023. The PSUs vested at 100% of the target award and include dividend equivalents accrued during the three-year performance period.
F2: Shares withheld for payment of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 23, 2023 Filed Aug 25, 2023 18:30 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantStock Options · Derivative | 75,541 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001944048-23-000060 · wk-form4_1693002588.xml · derivative · entry 8 Tillett Caroline · CIK 0001966949 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,541 Underlying: Common Stock · 75,541 shares Expires 2032-02-14 F7 · security: These stock options were originally granted by Johnson & Johnson and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into options with respect to Issuer common stock with adjustments made to the number of shares subject to the award and its exercise price in order to preserve the award's value. F3 · derivative.exercise_date: This award will vest in full on 02/14/2025, subject to the reporting person's continued service through the vesting date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 18:30 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantStock Options · Derivative | 74,422 | $0.00 Strike: $21.97 | $0.00 |
DisclosureSEC source: 0001944048-23-000060 · wk-form4_1693002588.xml · derivative · entry 7 Tillett Caroline · CIK 0001966949 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,422 Underlying: Common Stock · 74,422 shares Expires 2033-02-13 F7 · security: These stock options were originally granted by Johnson & Johnson and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into options with respect to Issuer common stock with adjustments made to the number of shares subject to the award and its exercise price in order to preserve the award's value. F2 · derivative.exercise_date: This award vests in three equal installments on 02/13/2024, 02/13/2025, and 02/13/2026, subject to the reporting person's continued service through the vesting date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 18:30 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantRestricted Stock Units · Derivative | 21,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001944048-23-000060 · wk-form4_1693002588.xml · derivative · entry 6 Tillett Caroline · CIK 0001966949 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,321 Underlying: Common Stock · 21,321 shares Expires not disclosed F5 · security: These RSUs were originally granted by Johnson & Johnson as performance share units and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into time-based RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value and with performance criteria deemed satisfied at the target level, unless two years have been completed in the performance period, in which case performance was deemed satisfied at the level of performance for such years. F5 · derivative.exercise_price: These RSUs were originally granted by Johnson & Johnson as performance share units and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into time-based RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value and with performance criteria deemed satisfied at the target level, unless two years have been completed in the performance period, in which case performance was deemed satisfied at the level of performance for such years. F4 · derivative.exercise_date: This award will vest in full on 02/08/2024, subject to the reporting person's continued service through the vesting date. F4 · derivative.expiration_date: This award will vest in full on 02/08/2024, subject to the reporting person's continued service through the vesting date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 18:30 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantRestricted Stock Units · Derivative | 19,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001944048-23-000060 · wk-form4_1693002588.xml · derivative · entry 5 Tillett Caroline · CIK 0001966949 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,121 Underlying: Common Stock · 19,121 shares Expires not disclosed F5 · security: These RSUs were originally granted by Johnson & Johnson as performance share units and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into time-based RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value and with performance criteria deemed satisfied at the target level, unless two years have been completed in the performance period, in which case performance was deemed satisfied at the level of performance for such years. F5 · derivative.exercise_price: These RSUs were originally granted by Johnson & Johnson as performance share units and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into time-based RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value and with performance criteria deemed satisfied at the target level, unless two years have been completed in the performance period, in which case performance was deemed satisfied at the level of performance for such years. F3 · derivative.exercise_date: This award will vest in full on 02/14/2025, subject to the reporting person's continued service through the vesting date. F3 · derivative.expiration_date: This award will vest in full on 02/14/2025, subject to the reporting person's continued service through the vesting date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 18:30 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantRestricted Stock Units · Derivative | 23,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001944048-23-000060 · wk-form4_1693002588.xml · derivative · entry 4 Tillett Caroline · CIK 0001966949 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,158 Underlying: Common Stock · 23,158 shares Expires not disclosed F5 · security: These RSUs were originally granted by Johnson & Johnson as performance share units and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into time-based RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value and with performance criteria deemed satisfied at the target level, unless two years have been completed in the performance period, in which case performance was deemed satisfied at the level of performance for such years. F5 · derivative.exercise_price: These RSUs were originally granted by Johnson & Johnson as performance share units and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into time-based RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value and with performance criteria deemed satisfied at the target level, unless two years have been completed in the performance period, in which case performance was deemed satisfied at the level of performance for such years. F6 · derivative.exercise_date: This award will vest in full on 02/13/2026, subject to the reporting person's continued service through the vesting date. F6 · derivative.expiration_date: This award will vest in full on 02/13/2026, subject to the reporting person's continued service through the vesting date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 18:30 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantRestricted Stock Units · Derivative | 6,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001944048-23-000060 · wk-form4_1693002588.xml · derivative · entry 3 Tillett Caroline · CIK 0001966949 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,675 Underlying: Common Stock · 6,675 shares Expires not disclosed F1 · security: These restricted share units ("RSUs") were originally granted by Johnson & Johnson and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 20223 (the "Separation") and pursuant to the terms of the Employee Matters Agreement, dated as of May 3, 2023 between Johnson & Johnson and the Issuer (the "Employee Matters Agreement"), were converted into RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value. F1 · derivative.exercise_price: These restricted share units ("RSUs") were originally granted by Johnson & Johnson and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 20223 (the "Separation") and pursuant to the terms of the Employee Matters Agreement, dated as of May 3, 2023 between Johnson & Johnson and the Issuer (the "Employee Matters Agreement"), were converted into RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value. F4 · derivative.exercise_date: This award will vest in full on 02/08/2024, subject to the reporting person's continued service through the vesting date. F4 · derivative.expiration_date: This award will vest in full on 02/08/2024, subject to the reporting person's continued service through the vesting date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 18:30 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantRestricted Stock Units · Derivative | 7,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001944048-23-000060 · wk-form4_1693002588.xml · derivative · entry 2 Tillett Caroline · CIK 0001966949 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,645 Underlying: Common Stock · 7,645 shares Expires not disclosed F1 · security: These restricted share units ("RSUs") were originally granted by Johnson & Johnson and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 20223 (the "Separation") and pursuant to the terms of the Employee Matters Agreement, dated as of May 3, 2023 between Johnson & Johnson and the Issuer (the "Employee Matters Agreement"), were converted into RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value. F1 · derivative.exercise_price: These restricted share units ("RSUs") were originally granted by Johnson & Johnson and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 20223 (the "Separation") and pursuant to the terms of the Employee Matters Agreement, dated as of May 3, 2023 between Johnson & Johnson and the Issuer (the "Employee Matters Agreement"), were converted into RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value. F3 · derivative.exercise_date: This award will vest in full on 02/14/2025, subject to the reporting person's continued service through the vesting date. F3 · derivative.expiration_date: This award will vest in full on 02/14/2025, subject to the reporting person's continued service through the vesting date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 18:30 UTC | Kenvue Inc. KVUE · Entity 3098 | GrantRestricted Stock Units · Derivative | 8,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001944048-23-000060 · wk-form4_1693002588.xml · derivative · entry 1 Tillett Caroline · CIK 0001966949 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,994 Underlying: Common Stock · 8,994 shares Expires not disclosed F1 · security: These restricted share units ("RSUs") were originally granted by Johnson & Johnson and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 20223 (the "Separation") and pursuant to the terms of the Employee Matters Agreement, dated as of May 3, 2023 between Johnson & Johnson and the Issuer (the "Employee Matters Agreement"), were converted into RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value. F1 · derivative.exercise_price: These restricted share units ("RSUs") were originally granted by Johnson & Johnson and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 20223 (the "Separation") and pursuant to the terms of the Employee Matters Agreement, dated as of May 3, 2023 between Johnson & Johnson and the Issuer (the "Employee Matters Agreement"), were converted into RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value. F2 · derivative.exercise_date: This award vests in three equal installments on 02/13/2024, 02/13/2025, and 02/13/2026, subject to the reporting person's continued service through the vesting date. F2 · derivative.expiration_date: This award vests in three equal installments on 02/13/2024, 02/13/2025, and 02/13/2026, subject to the reporting person's continued service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.